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OBJECTIVE: The objective of this selective EBM review is to determine “Is platelet-rich 
plasma injection effective for reducing pain & symptom severity in adults with carpal tunnel 
syndrome?” 
STUDY DESIGN: Systematic review of two randomized controlled trials and one non-
randomized controlled trial to analyze the overall effectiveness of platelet-rich plasma (PRP) 
injections as a management for carpal tunnel syndrome (CTS). All three articles were published 
in peer-reviewed journals after the year 2016. 
DATA SOURCES: These two RCTs and one non-RCT were found using Pubmed and were 
selected based on their year of publication, population of individuals with mild to moderate CTS, 
relevance to clinical question, and ability to meet POEM criteria. 
OUTCOMES MEASURED: Patients in these three studies reported pain level measured by the 
Visual Analog Scale (VAS) and symptom severity measured by the Symptom Severity Scale 
(SSS) 
RESULTS: Raeissadat et al. reported that PRP is not an effective treatment for CTS since there 
was no statistically significant evidence to support that at 10 weeks, PRP injections with a wrist 
splint added any benefit in VAS and SSS scoring compared to splinting alone (BMC 
Musculoskelet Disord. 2018;19(1). doi:10.1186/s12891-018-1963-4.). Wu et al. concluded that 
PRP is an effective treatment for CTS if used for 6 months. However, applying an endpoint of 3 
months to make the study directly comparable to the others shows that a 3 month treatment 
period was not long enough to demonstrate statistically significant benefit of using PRP on the 
VAS, despite yielding statistically significant positive results on the SSS in month 3 (Sci Rep. 
2017;7(1). doi:10.1038/s41598-017-00224-6.). In contrast, Atwa et al. showed that at the 1 and 3 
month follow-ups, PRP injections were sometimes significantly better in relieving pain and 
symptom severity than corticosteroid injections since the PRP group overall scored lower on the 
VAS and SSS with p values <0.05 at both times, however the standard deviation was high 
enough to cause concern in the validity of these results. (The Egypt Rheum. 2018. 
doi:10.1016/j.ejr.2018.07.008.). 
CONCLUSIONS: Based on the three studies analyzed, it can be concluded that PRP injection is 
not an effective treatment for reducing pain and symptom severity in adults with CTS. 











Carpal tunnel syndrome (CTS) is a type of peripheral entrapment neuropathy associated 
with etiologies such as repetitive overuse of the wrist. Other causes may include trauma, 
pregnancy, and specific disease pathophysiology like diabetes mellitus, sarcoidosis, amyloidosis, 
obesity, arthritis and hypothyroidism. Regardless of the specific cause, symptoms such as pain, 
numbness, tingling, and loss of muscle strength in the median nerve innervation arise from 
compression of the median nerve in the carpal tunnel under the transverse carpal ligament. 
Patients complain of an irritating and even painful sensation that radiates down their forearm into 
components of their hand, making the fingers feel weighted and unusable. Symptoms may also 
spread upwards towards the arm and shoulder of the affected limb. Regardless of the location of 
pain, patients typically see no erythema or edema.1 
CTS makes up 90% of peripheral nerve entrapment cases,2 and without intervention, CTS 
can significantly limit daily activities, hindering individuals’ overall quality of life and ability to 
function.3 In 2011, it was estimated that 2.7-5.8% of the general population had carpal tunnel 
syndrome, and the average annual incidence was 329 per 100,000 person-years.1 
Each year in the US, CTS accounts for a total cost of $2 billion in medical costs. Mostly 
due to the surgical procedures required to relieve symptoms of this condition, carpal tunnel 
syndrome can be considered the most expensive upper extremity musculoskeletal disorder in the 
United States.4 Not only does this condition cost actual dollars, but it can take away from time in 
the workplace, ultimately leaving most individuals with a lower income, and some, without a 
job. In fact, the average annual time missed from work due to carpal tunnel-related 
disability is 27 days. Surprisingly, this data only comes second to fractures in missed workdays.4 
Additionally, it has been noted that within 18 months of beginning a job, when an individual 
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worker develops CTS, there is an 18% chance they will inherently leave that job due to it.4 CTS 
is undoubtedly a detrimental disorder to the United States population financially, functionally, 
and emotionally. 
It is not known how many yearly healthcare visits occur from CTS, but it is known that 
CTS is more common in the working populations at an incidence of 5-21%,4 mostly seen in 
occupations where repetitive wrist motions are necessary. Examples of such occupations include 
food processing, the logging industry, and carpentry. This is compared to a lower incidence in 
the general population at 1-5%.4 
It is known that CTS is due to the physical compression of the median nerve in the 
transverse carpal ligament of the wrist. Typically, there is a traceable pattern of symptoms over 
the patient’s hand and forearm that follow the median nerve innervation which helps guide the 
diagnosis of CTS using physical exam techniques such as Tinel sign, Phalen maneuver, or a flick 
sign. However, 9% of patients can have a symptomatic presentation that is unusual for the 
diagnosis which can prolong the diagnostic period or require additional tests.1 If not treated 
properly, CTS can lead to permanent nerve damage of the affected regions.1 
There are measures for CTS treatment that are typically used as a first-line treatment 
before decompression surgery. These modalities include wrist splints, NSAIDs, corticosteroid 
injections, and physical therapy. Unfortunately, it was reported that close to 60-70% of 
individuals undergoing these conventional management techniques remain symptomatic after 18 
months.4 Surgical decompression is certainly more effective than the alternative methods 
mentioned, but it has a large range of failure rates at 7-75%.5 It is only truly suggested for 
patients with severe CTS or for patients with symptoms that are highly resistance to the 
previously mentioned measures of management.5 Due to the substantial disability this condition 
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holds, research into effective treatment regimens is most certainly warranted. The newest 
research being conducted is on the use of platelet-rich-plasma (PRP) injections as an alternative 
to the current mainstays of treatment. PRP is a mixture dense in platelets and growth factors that 
has been previously used for wound healing and angiogenesis in the fields of neurosurgery, 
dentistry, and cosmetics, and there is strong evidence for its effectiveness in axon regeneration 
and repair of neurons. Using this knowledge as a basis for its therapeutic use, PRP could possibly 
become a treatment option for patients to relieve CTS symptoms, prolonging their need for 
decompression surgery or even preventing it altogether. This review uses 2 RCTs and 1 non-
RCTs to analyze the overall effectiveness of PRP injections as a management for the symptoms 
of CTS. 
OBJECTIVE  
          The objective of this selective EBM review is to determine “Is platelet rich plasma 
injection effective for reducing pain & symptom severity in adults with carpal tunnel 
syndrome?” 
METHODS 
            All research and interpretation for this review including specific article selection were 
completed by the author. Three studies published in the English language were analyzed in this 
systematic review and were found using Pubmed and the keywords Platelet-rich Plasma and 
Carpal Tunnel Syndrome. Articles were selected based on their relevance to the clinical question, 
year of publication after 2016, population of individuals with mild-moderate CTS, and ability to 
meet POEM criteria. Exclusion criteria for this study included disease-oriented evidence, 
population under 20-years-old and above 60-years-old, articles written in a language other than 
English, and previously published Cochrane systematic reviews. Two of these studies were 
randomized control trials, while one was a non-randomized control trial, but they all analyzed 
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whether PRP is an effective treatment for mild to moderate CTS. The outcome measures used 
and analyzed in all three of these trials were the Visual Analogue Scale (VAS) and the Symptom 
Severity Scale (SSS) of the Boston Carpal Tunnel Questionnaire (BCTQ).2, 3, 5 The intervention 
used in these trials was platelet rich plasma injections (PRP) into the median nerve and PRP 
combined with splinting, and it was compared to the interventions of corticosteroid injections 
into the median nerve as well as wrist splinting alone.2, 3, 5 The statistics of this study were found 
using p-values, standard deviation and mean change from baseline. The patient demographics 
and criteria met for each article are described in Table 1. 
Table 1.  Demographics & Characteristics of included studies 
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medicine/rehab 
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OUTCOMES MEASURED 
        The outcomes measured in this study included pain level change using the Visual 
Analogue Scale (VAS) and change in severity of symptoms using the Symptom Severity Scale 
(SSS). Data was collected through both of these measurement scales by subjects self-reporting 
pain and symptom severity. The VAS is a tool for patients to rate their pain on a scale of 0 (no 
pain) to 10 (worst pain) using pictures for reference. The SSS is a component of the BCTQ 
where patients rate their severity of CTS symptoms using an 11-question questionnaire with each 
question scaled 1 (least severe) to 5 (most severe), making a total possibility of 55 points to 
gauge severity of symptoms. Raeissadat et al.2 measured these two outcomes at 10 weeks, Wu et 
al.5 at 1, 3 and 6 months, and Atwa et al.3 at 1 and 3 months to determine the efficacy of PRP 
injections for CTS. The endpoint of this review is set at 3 months. 
RESULTS 
This review uses three different studies to compare multiple forms of therapy for CTS 
with the intention to explain whether PRP injection is an effective treatment for CTS. All three 
studies include adults between the ages of 20 and 60 years old. Keeping in mind that the 
Raeissadat et al.2 study concluded at 10 weeks, and the Wu et al.5 and Atwa et al.3 studies 
collected data at 3 months, the end point of this study is set at 3 months, noting this two-week 
discrepancy. 
The study by Raeissadat et al.2 is a randomized trial conducted at Shahid Beheshti 
University of Medical Sciences to show the safety and efficacy of PRP injections in the 
treatment of CTS. It used 41 women, placing 20 in the control group and 21 in the treatment 
group. All 41 subjects completed the trial. An overnight prefabricated wrist splint at 5 degree 
extension was used on the control group for 8 weeks.2 The treatment group was treated with the 
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same splinting regimen but also with a median nerve injection of 1mL of autologous PRP. The 
mean change in each group of variables of VAS and SSS were recorded after 10 weeks.2 
Inclusion and exclusion criteria for this study can be found in Table 1. Although there was a 
mean decrease in both treatment and control groups of pain and symptom severity, the data 
displayed in Table 2 does not support the benefit of using PRP in addition to splinting as a 
treatment option for CTS.2 Ultimately, with standard deviations calculated very close to the 
means and with p values considerably larger than 0.05, there is no statistically significant 
evidence to support the claim that PRP is effective for CTS treatment.2 
Table 2. Pain & symptom severity reduction at 10 weeks by Raeissadat et al. 
Variables Group Mean SD P value (adjusted for age) 
VAS change 10 wks Control (n = 20) -2.90 2.1  
 
0.398 
    Treatment (n = 21) -2.76 2.4 
SSS change 10 wks Control (n = 20) -0.70 0.3  
 
0.629 
    Treatment (n = 21) -0.72 0.7 
  The study conducted by Wu et al.5 is a single-blind randomized trial that used 60 
participants, 30 in the treatment and 30 in the control group to determine the six-month efficacy 
of PRP for CTS. All 60 participants completed the study. The research was conducted at the Tri-
Service General Hospital, National Defense Medical Center in Taiwan, Republic of China. A 
total of 3mL of autologous ultrasound-guided PRP injection was used in subjects in the treatment 
group while subjects in the control group wore a wrist splint alone in the neutral position for at 
least 8 hours a day during the time of the study.5 Inclusion and exclusion criteria for this study 
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can be found in Table 1. The mean change of the variables VAS and SSS was measured at 1 
month, 3 months, and 6 months. Due to the limited time frames in the Raeissadat et al.2 and 
Atwa et al.3 studies at 10 weeks and 3 months respectively, the data in this study collected at 
month 6 will not be considered in this review with an endpoint of 3 months. It was seen that both 
groups in this study displayed a reduction in both pain and symptom severity at 1, and 3 months, 
however, only the SSS data at month 3 can be used as supporting evidence towards PRP 
injections effectiveness in CTS due to it being the only data within the 3 month endpoint with a p 
value <0.05 and standard reasonably low deviation.5 
Table 3. 1, 3, and 6 month change in pain and symptom severity in corticosteroid vs PRP 
group as measured by VAS and SSS by Wu et al. 
  PRP Group (n = 30) Control Group (n = 30)   
p value Mean Difference + SF Mean Difference + SF 
VAS-Pre (6.50 + 0.30) (6.29 + 0.31)   
VAS month 1 -2.61 + 0.26 -2.41 + 0.20 0.540 
VAS month 3 -3.59 + 0.34 -2.93 + 0.20 0.104 
VAS month 6 -4.53 + 0.37 -3.30 + 0.34 0.018 
SSS-Pre (26.17 + 1.10) (24.93 + 1.22)   
SSS month 1 -8.93 + 1.10 -6.50 + 0.94 0.098 
SSS month 3 -10.47 + 1.17 -6.80 + 0.93 0.017 
SSS month 6 -11.76 + 1.21 -8.73 + 0.85 0.045 
  The study by Atwa et al.3 was conducted to study PRP versus corticosteroid injections for 
treatment of CTS symptoms. It used 36 patients who all completed the trial, 18 patients in the 
control group receiving a single injection of the corticosteroid methylprednisolone 40mg/1.0mL 
and 18 patients in the treatment group receiving PRP injections of 2mL into the median nerve 
with 24 hours of rest following PRP injections.3 Subjects were recruited from the Rheumatology 
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and Rehabilitation outpatient clinic, Zagazig University Hospitals. Table 1 outlines the inclusion 
and exclusion criteria of the study. The mean change of VAS and SSS were measured at 1 and 3 
month periods.3 The results showed with great confidence represented by the p intervals <0.05 
that there was a significant total decrease in pain and symptom severity from baseline in both the 
treatment and control groups at 1 and 3 months although there was a slight increase in pain and 
symptom severity from 1 to 3 months in both groups. However, it can be said that the most 
significant decrease in pain and symptom severity at both 1 and 3 months from baseline was 
found in the group treated with PRP. On the other hand, despite the low p values, the large 
standard deviations on the mean values are a cause for concern. By definition of standard 
deviation, 99.7% of the data lies within 3 standard deviations of the mean in a normal 
distribution. This suggests that there may have been data points very far from the mean, which 
contradicts the notion that PRP was an effective treatment as a whole. Therefore, this study is not 
entirely supportive of the effectiveness of PRP to treat CTS. 
Table 4. 1 and 3 month change in pain and symptom severity in CS vs PRP injections as 
measured by VAS and SSS by Atwa et al. 
Parameter mean + SD   Group I Corticosteroid (n = 
18) 
Group II PRP (n = 18) p value 
VAS Baseline 7.2 + 1.3 7.05 + 1.4 0.8 
  1 month 3.5 + 2.35 2.1 + 2.6 0.03 
  3 months 5.2 + 1.9 3.4 + 2.09 0.002 
  p value 0.0001 0.0001   
SSS Baseline 36.8 + 7 33.2 + 6 0.1 
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  1 month 22.3 + 7.4 18.6 + 10.7 0.02 
  3 months 28.6 + 6.8 21.5 + 10.2 0.001 
  
DISCUSSION 
        Although treatments such as corticosteroid injections, wrist splinting, and NSAIDs exist, 
they unfortunately have little to no permanent effect for patients who severely suffer from 
symptoms of this syndrome. Patients are left with the option of invasive decompression surgery 
that commonly brings its own risks such as adjacent vessel damage, sensitive scarring and 
infection.5 This selective evidence-based medicine review focused on the specific use of PRP 
injections as a treatment option for CTS and studied its use for pain and symptom severity in a 3 
month time frame. PRP injections have been used to promote healing for alternative means such 
as orthopedic, dental and plastic surgery procedures since the late 1980s.6 This review does not 
support much promise towards the use of PRP injections for CTS treatment. The Atwa et al. 
study when compared to standard treatments of splinting and corticosteroid injection use would 
have been very supportive if it were not for the large standard deviations.3 The studies conducted 
by Raeissadat et al. and Wu et al. did not strongly and statistically show support for the 
effectiveness of PRP for CTS treatment either outside of the Wu et al. study’s SSS results at 3 
months.2, 5 
        It should be noted that none of the three studies analyzed were conducted in the United 
States nor were US studies on this topic found; therefore, the use of PRP injections in individuals 
outside of the United States may play a factor in this treatment option’s efficacy in these trials. 
Although the use of activated PRP injections are not approved by the FDA and must be used 
“off-label” in the US, and there is no evidence to support its availability for use in the US, it is 
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being explored in other countries for the use described in this study. It should also be noted that 
PRP use for other therapies has been deemed safe when mixed with other substances, but it has 
seen its drawbacks such as for its use in musculoskeletal pain where side effects of local 
infection and pain at the site of the injection can be seen.6  
Limitations to these studies are evident and may have played a role in the final outcome 
of the studies. Concerning the article by Raeissadat et al.,2 in both the control and treatment 
group, data on the patient population was halted at 10 weeks. Conversely, the Atwa et al.3 and 
Wu et al.5 studies were conducted to 1 and 3 months and 1, 3 and 6 months respectively. 
Although these were indeed short follow-up times, these inconsistent time frames made it 
difficult to choose an endpoint for this review. With the final endpoint chosen at 3 months, there 
is an obvious two-week discrepancy between the Wu et al.5 and Atwa et al.3 studies when 
compared to Raeissadat et al.,2 leaving room for a potential change in outcome if the Raeissadat 
et al.2 study had been conducted two weeks longer. The longer studies also could have benefitted 
by questioning subjects at monthly intervals instead of at multiple month intervals. Other 
limitations include small sample sizes, lack of double-blinding in all three studies and lack of 
randomization in the Atwa et al. study.3 In order to make an even stronger statement concerning 
the value of PRP injection for CTS treatment, these limitations must be addressed in future 
studies. 
CONCLUSIONS 
         After analyzing these three studies for the purpose of this review, it can be concluded that 
PRP is not an effective treatment for CTS. The most support for this conclusion is found in the 
Wu et al. study which showed PRP benefit throughout the entire six-month study when 
compared to night splinting, but the data was provided with p values >0.05 at SSS month 1, and 
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VAS month 1 and 3, making the data at these time frames statistically insignificant. However, 
PRP injections showed benefit in regard to SSS at 3 and 6 months and VAS at 6 months with p 
values <0.05, but due to this review’s endpoint being 3 months, it can only be stated that Wu et 
al. shows support for PPR injections for treatment of CTS’s SSS at 3 months. The study by 
Raeissadat et al.2 did not provide sufficient statistical evidence to support the claim that PRP 
adds any benefit to patient’s CTS symptoms. Although both treatment and control groups 
displayed a decrease in pain and symptom severity at 10 weeks, the p values were >0.05 and 
standard deviations were large, making the data statistically insignificant. The final study by 
Atwa et al.3 also supported the same conclusion. Although there was a significant decrease in 
pain and symptom severity in both the PRP and control group with p values <0.05 at both 1 and 
3 months, PRP did display the greatest decrease in pain and symptom severity, showing some 
support for PRP effectiveness in CTS treatment. However, due to large standard deviations in the 
mean values recorded, there is ample room to doubt the effectiveness of the use of PRP in the 
treatment of CTS. Future studies would warrant larger sample sizes in order to achieve more 
conclusive data. Research would also benefit by selecting a study endpoint as well as a dose of 









Latimer, PRP treatment for carpal tunnel syndrome  11 
REFERENCES 
1.      LeBlanc, KE. Carpal Tunnel Syndrome. Am Fam Physician. 2011;83(8):952-958 
2.      Raeissadat SA, Karimzadeh A, Hashemi M, Bagherzadeh L. Safety and efficacy of 
platelet-rich plasma in treatment of carpal tunnel syndrome; a randomized controlled trial. BMC 
Musculoskelet Disord. 2018;19(1). doi:10.1186/s12891-018-1963-4. 
3.   Atwa ET, Esh AM, Al ITAE, Awad YM. Platelet-rich plasma versus corticosteroid 
injections for carpal tunnel syndrome: Clinical and electrophysiological study. The Egypt Rheum. 
2018. doi:10.1016/j.ejr.2018.07.008. 
4.      Dale AM, Harris-Adamson C, Rempel D, et al. Prevalence and incidence of carpal tunnel 
syndrome in US working populations: pooled analysis of six prospective studies. Scand J Work 
Environ Health. 2013;39(5): 495-505. doi:10.5271/sjweh.3351. 
5.   Wu Y-T, Ho T-Y, Chou Y-C, et al. Six-month efficacy of platelet-rich plasma for carpal 
tunnel syndrome: A prospective randomized, single-blind controlled trial. Sci Rep. 2017;7(1). 
doi:10.1038/s41598-017-00224-6. 
6.      Stanford School of Medicine, Department of Radiology, Platelet Rich Plasma (PRP) 
Injection - Information and Instructions for Patients, date unknown. 
  
  
  
 
